Concepedia

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity

Vasileios Fragoulakis, Rossana Roncato, Chiara Dalle Fratte, Fabrizio Ecca, Marina Bartsakoulia, Federico Innocenti, Giuseppe Toffoli, Erika Cecchin, George P. Patrinos, Christina Mitropoulou

The American Journal of Human Genetics · 2019 · 52 citations · 26 references

DOIFull text

Open access

Concepts

References

26

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

, , +16

Multiple regression of cost data: use of generalised linear models

Julie Barber, Simon Thompson · Journal of Health Services Research & Policy · 2004 · 405 citations

, , +12

Estimating medical costs with censored data

Heejung Bang · Biometrika · 2000 · 362 citations

, , +16

Health state utilities for metastatic breast cancer

Andrew Lloyd, Beenish Nafees, J Narewska et al. · British Journal of Cancer · 2006 · 362 citations · Full text

, , +17

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 345 citations · Full text

, , +17